NANO-X IMAGING LTD: stock overview

NNOXNASDAQHealthcare · X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Price

$0.23

November 20, 2026Market cap $16M

What Ploutos Investor adds for NANO-X IMAGING

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

NANO-X IMAGING had revenue of $13M in the fiscal year to December 31, 2025 and a net loss of $75M. Revenue grew by 77.8% a year on average over the last 4 years. It holds more cash than debt, by $46M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$16M
69.59M shares
P/E
–
Revenue, fiscal year
$13M
+77.8% a year over 4 years
Net margin
-576.1%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+14.7% a year over 2 years

Fiscal years in figures

NNOX's revenue, profit, cash flow and dividend with each year-end price, from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $368M
$16M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 1.9
0.1
FCF yield 3-year median: -13.1%
–
Earnings yield 3-year median: -17.0%
–

Profitability

Gross margin 
-98.2%
Operating margin 
-600.8%
Net margin 3-year median: -576.1%
-576.1%
ROIC 
-43.3%
ROIC, 5-year average 
-30.1%
ROE, fiscal year 
-53.7%

Growth

Revenue, yearly change 
+15.4%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+77.8%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$49M
Total debt 
$7.9M
Of which operating leases 
$4.7M
Net cash 
$46M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+9.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Nano-X Imaging Ltd.
Exchange
NASDAQ
Industry (SIC)
3844 · X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
69.59M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do NANO-X IMAGING's filings show?

These are NANO-X IMAGING's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NNOX

Didn't find what you were looking for?

Ask us
What is NNOX's market cap?

NANO-X IMAGING LTD's market cap is $16M, at a price of $0.23 on November 20, 2026 and 69.59M shares.

How much revenue does NNOX have?

NANO-X IMAGING had revenue of $13M in the fiscal year to December 31, 2025. Over the last 4 years it changed by +77.8% a year on average.

Does NNOX pay a dividend?

No. NANO-X IMAGING paid no regular dividend over the last 12 months.

Where do the figures come from?

From NANO-X IMAGING LTD's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.